The Irish company is building a portfolio of first-in-class treatments that target multiple mechanisms of the most aggressive forms of cancer.

In December 2022, Carrick announced it had raised $25 million in a Series C financing that will fund ongoing and planned samuraciclib clinical trials, ongoing development of its CDK12/13 inhibitor/Cyclin-K glue-degrader, and for working capital and general corporate purposes.